Free Trial
NASDAQ:CUE

Cue Biopharma (CUE) Stock Price, News & Analysis

Cue Biopharma logo
$0.69 +0.02 (+2.91%)
Closing price 04:00 PM Eastern
Extended Trading
$0.70 +0.01 (+0.87%)
As of 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cue Biopharma Stock (NASDAQ:CUE)

Key Stats

Today's Range
$0.65
$0.71
50-Day Range
$0.58
$0.86
52-Week Range
$0.45
$1.99
Volume
224,880 shs
Average Volume
408,446 shs
Market Capitalization
$52.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Buy

Company Overview

Cue Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

CUE MarketRank™: 

Cue Biopharma scored higher than 82% of companies evaluated by MarketBeat, and ranked 214th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cue Biopharma has received no research coverage in the past 90 days.

  • Read more about Cue Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Cue Biopharma are expected to grow in the coming year, from ($0.76) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cue Biopharma is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cue Biopharma is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cue Biopharma has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cue Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    1.24% of the float of Cue Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Cue Biopharma has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Cue Biopharma has recently increased by 7.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cue Biopharma does not currently pay a dividend.

  • Dividend Growth

    Cue Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.24% of the float of Cue Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Cue Biopharma has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Cue Biopharma has recently increased by 7.43%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cue Biopharma has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Cue Biopharma this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for CUE on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cue Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.26% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 35.04% of the stock of Cue Biopharma is held by institutions.

  • Read more about Cue Biopharma's insider trading history.
Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CUE Stock News Headlines

Cue Biopharma Amends License Agreement with MIL 40G
Dalio heeds Buffett’s warning… [$319 million stake in gold]
Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks.
Cue Biopharma CFO to Resign
See More Headlines

CUE Stock Analysis - Frequently Asked Questions

Cue Biopharma's stock was trading at $1.09 at the start of the year. Since then, CUE shares have decreased by 36.5% and is now trading at $0.6920.
View the best growth stocks for 2025 here
.

Cue Biopharma, Inc. (NASDAQ:CUE) announced its quarterly earnings data on Monday, May, 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The business had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.90 million. Cue Biopharma had a negative net margin of 507.87% and a negative trailing twelve-month return on equity of 228.43%.

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

Last Earnings
5/12/2025
Today
7/02/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CUE
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$4.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+333.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.67 million
Net Margins
-507.87%
Pretax Margin
-507.87%

Debt

Sales & Book Value

Annual Sales
$9.29 million
Price / Cash Flow
N/A
Book Value
$0.28 per share
Price / Book
2.47

Miscellaneous

Free Float
66,112,000
Market Cap
$52.14 million
Optionable
Optionable
Beta
1.43
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CUE) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners